Heart rate reduction is probably not the main beneficial mechanism by which beta blockade improves outcome in patients with systolic chronic heart failure.
Fragasso
Gabriele
G
Salerno
Anna
A
Margonato
Alberto
A
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002227:Carbazoles / Q000627:therapeutic use*; D000077261:Carvedilol; D002908:Chronic Disease; D054143:Heart Failure, Systolic / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D015994:Incidence; D011412:Propanolamines / Q000627:therapeutic use*; D012307:Risk Factors; D040242:Risk Reduction Behavior; D013318:Stroke Volume / Q000187:drug effects; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol